Eliminating Enzyme-Dependent Purification to Enable Scalable & Commercially Viable Circular RNA Manufacturing
- Exploring how enzyme-free purification strategies can overcome key manufacturing bottlenecks in circular RNA development while improving scalability, recovery, and product purity
- Discussing the commercial and CMC implications of reducing purification complexity, lowering cost-per-dose, and minimizing supply chain dependency across clinical-tocommercial manufacturing
- Sharing early regulatory, process development, and scale-up considerations from advancing circular RNA therapeutics toward first-in-human studies